Glutamate-Related Antibodies and Peripheral Insulin-Like Growth Factor in Bipolar Disorder and Lithium Prophylaxis

Ferensztajn-Rochowiak Ewa; Kaczmarek Mariusz; Wojcicka MarlenaKaufman-Szukalska ElzbietaDziuda SebastianRemlinger-Molenda AgnieszkaSzeliga-Neymann AgnieszkaLosy JacekRybakowski Janusz K.

首页> 外文期刊>Neuropsychobiology >Glutamate-Related Antibodies and Peripheral Insulin-Like Growth Factor in Bipolar Disorder and Lithium Prophylaxis

【24h】

Glutamate-Related Antibodies and Peripheral Insulin-Like Growth Factor in Bipolar Disorder and Lithium Prophylaxis

机译：Glutamate-Related Antibodies and Peripheral Insulin-Like Growth Factor in Bipolar Disorder and Lithium Prophylaxis

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Aims: The aim of this study was to evaluate serum levels of the antineuronal antibodies anti-N-methyl-D-aspartate receptor (NMDAR) and anti-glutamic acid decarboxylase (GAD), and insulin-like growth factor 1 (IGF-1), in patients with bipolar disorder (BD), during manic and depressive episodes and in remission compared to euthymic patients receiving long-term lithium therapy. Methods: Serum levels of anti-NMDAR and anti-GAD 450/620 antibodies, as well as IGF-1, were measured using the ELISA method in 19 manic and 17 depressed patients both in an acute episode and in remission after the episode. All of the subjects were under pharmacological treatment. The control group included 18 euthymic BD patients receiving lithium for 9-44 years (mean 22 +/- 11) in whom a single measurement was performed. Results: Serum levels of anti-NMDAR antibodies were higher in acute manic episodes than in lithium-treated patients. Serum levels of anti-GAD 450/620 antibodies were higher in acute manic and depressive episodes compared to remission after the respective episode. Their values in both acute manic and depressive episodes were higher than those in lithium-treated patients. Serum levels of IGF-1 were higher in acute manic episodes and in remission after mania than in lithium-treated patients. Conclusion: Higher levels of anti-NMDAR and anti-GAD antibodies during episodes may point to an abnormality in the glutamatergic system in BD. Increased levels of IGF-1 during an acute manic episode and in remission after mania may constitute a compensatory mechanism against excitotoxicity. Lower levels of anti-NMDAR, anti-GAD antibodies, and IGF-1 during long-term lithium treatment may reflect normalization of this processes, contributing to mood stabilization.

著录项

来源
《Neuropsychobiology》 |2019年第1期|49-56|共8页
作者
Ferensztajn-Rochowiak Ewa; Kaczmarek Mariusz; Wojcicka MarlenaKaufman-Szukalska ElzbietaDziuda SebastianRemlinger-Molenda AgnieszkaSzeliga-Neymann AgnieszkaLosy JacekRybakowski Janusz K.;
展开▼
作者单位

Poznan Univ Med Sci, Dept Adult Psychiat, Ul Szpitalna 27-33, PL-60572 Poznan, Poland;

Poznan Univ Med Sci, Dept Clin Immunol, Poznan, Poland;

Poznan Univ Med Sci, Dept Clin Neuroimmunol, Poznan, PolandPoznan Univ Med Sci, Dept Psychiat Genet, Poznan, Poland;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类神经病学与精神病学;
关键词
N-methyl-D-aspartate receptor antibodies; Glutamic acid decarboxylase antibodies; Insulin-like growth factor 1; Bipolar disorder; Lithium prophylaxis;

Glutamate-Related Antibodies and Peripheral Insulin-Like Growth Factor in Bipolar Disorder and Lithium Prophylaxis

摘要

著录项

相关主题

期刊订阅